{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:51:22Z","timestamp":1787871082534,"version":"build-2784847793"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) ranks among the three most prevalent cancer-related diseases in terms of incidence. Hence, exploring drugs for HCC therapy is of great significance. Compounds with a diaryl urea structure have been reported to exhibit a broad range of biological activities, including anticancer activity. This study focuses on the specific diaryl urea derivative 4-(4-(3-(2-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide (SMCl), with particular emphasis on investigating its therapeutic effects against hepatocellular carcinoma (HCC) and elucidating the underlying molecular mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic> anti-cancer effects of SMCl were evaluated in HCC cell lines using MTS, colony formation, and wound healing assays. Western blot analyzed RAS\/RAF\/MEK\/ERK pathway modulation. <jats:italic>In vivo<\/jats:italic> efficacy was assessed using a xenograft model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. Western blot analysis demonstrated that SMCl effectively suppressed hepatocellular carcinoma proliferation by markedly inhibiting the RAS\/RAF\/MEK\/ERK signaling pathway, with this inhibitory effect exhibiting both time- and concentration-dependent characteristics. SMCl also demonstrated significant therapeutic efficacy in the xenograft tumor model, achieving a tumor inhibition rate of 72.37%. Notably, it showed no significant impact on spleen weight or body weight in mice, indicating low toxicity to normal tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study first elucidates the effects of SMCl on HCC cells and its impact on the RAS\/RAF\/MEK\/ERK signaling pathway, providing a potential active compound for the clinical treatment of liver cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1605515","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T07:38:36Z","timestamp":1752133116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS\/RAF\/MEK\/ERK pathway in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncai","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","article-title":"Hepatocellular carcinoma: molecular mechanisms and targeted therapies","volume":"55","author":"Alqahtani","year":"2019","journal-title":"Med. Kaunas. Lith."},{"key":"B2","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochimica Biophysica Acta Rev. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in immunotherapy for hepatocellular carcinoma (HCC)","volume":"30","author":"Bicer","year":"2023","journal-title":"Curr. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ijc.32119","article-title":"A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS\/RAF mutant cancer","volume":"145","author":"Cheng","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cells9010198","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11627","DOI":"10.18632\/oncotarget.3435","article-title":"\u03c8-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101567","DOI":"10.1016\/j.esmoop.2023.101567","article-title":"The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO\/world congress on gastrointestinal cancer, Barcelona","volume":"8","author":"Ducreux","year":"2023","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.2174\/0929867323666160411142532","article-title":"Diaryl urea: a privileged structure in anticancer agents","volume":"23","author":"Garuti","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2200341","DOI":"10.1002\/ardp.202200341","article-title":"Novel 2-oxo-2-phenylethoxy and benzyloxy diaryl urea hybrids as VEGFR-2 inhibitors: design, synthesis, and anticancer evaluation","volume":"356","author":"Ghannam","year":"2023","journal-title":"Archives Pharmacal Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"154821","DOI":"10.1016\/j.phymed.2023.154821","article-title":"Therapeutic targeting of Ras\/Raf\/MAPK pathway by natural products: a systematic and mechanistic approach for neurodegeneration","volume":"115","author":"Gravandi","year":"2023","journal-title":"Phytomedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/biom13081212","article-title":"A combination of conformation-specific RAF inhibitors overcome drug resistance brought about by RAF overexpression","volume":"13","author":"Imoto","year":"2023","journal-title":"Biomolecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4254\/wjh.v4.i3.99","article-title":"Hepatocellular carcinoma in developing countries: prevention, diagnosis and treatment","volume":"4","author":"Kew","year":"2011","journal-title":"World J. Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib\u2014Chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-019-03918-y","article-title":"Preclinical efficacy of a novel dual PI3K\/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma","volume":"84","author":"Kim","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3760\/cma.j.issn.0253-2727.2023.08.018","article-title":"Progress in molecular mechanisms and targeted therapies of persistent cancer cells","volume":"44","author":"Li","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.04.034","article-title":"Nanoscale metal\u2212organic frameworks for combined photodynamic and radiation therapy in cancer treatment","volume":"97","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0246","DOI":"10.1097\/HC9.0000000000000246","article-title":"Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma","volume":"7","author":"Liu","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3785\/j.issn.1008-9292.2015.09.01","article-title":"Research progress in toxicology of molecular targeted anticancer drugs","volume":"44","author":"Lou","year":"2015","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11418-023-01752-4","article-title":"Andrographolide anti-proliferation and metastasis of hepatocellular carcinoma through LncRNA MIR22HG regulation","volume":"78","author":"Luo","year":"2023","journal-title":"J. Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"628744","DOI":"10.3389\/fpubh.2021.628744","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature","volume":"9","author":"Ocran Mattila","year":"2021","journal-title":"Front. Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1039\/d3md00079f","article-title":"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole-based (thio)urea derivatives as potent antimicrobial agents against multi-drug-resistant Staphylococcus aureus and Mycobacterium tuberculosis","volume":"14","author":"Ommi","year":"2023","journal-title":"RSC Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1053\/j.gastro.2023.06.027","article-title":"Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter hepatocellular carcinoma early detection strategy (HEDS) study","volume":"165","author":"Reddy","year":"2023","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","article-title":"Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications","volume":"31","author":"Safri","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/1878-0261.13605","article-title":"Novel RAF-directed approaches to overcome current clinical limits and block the RAS\/RAF node","volume":"18","author":"Scardaci","year":"2024","journal-title":"Mol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1042\/BST20230552","article-title":"Regulation of RAF family kinases: new insights from recent structural and biochemical studies","volume":"52","author":"Spencer-Smith","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"B29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.acr.2022.01.007","article-title":"Implications of genetic heterogeneity in hepatocellular cancer","volume":"156","author":"Suresh","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.cgh.2023.04.005","article-title":"Liver transplantation 2023: status report, current and future challenges","volume":"21","author":"Terrault","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"110661","DOI":"10.1016\/j.biopha.2020.110661","article-title":"Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K\/AKT\/mTOR, and ROS pathways","volume":"131","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"114798","DOI":"10.1016\/j.biopha.2023.114798","article-title":"Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma","volume":"163","author":"Wei","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejphar.2015.06.032","article-title":"6-Shogaol induces cell cycle arrest and apoptosis in human hepatoma cells through pleiotropic mechanisms","volume":"762","author":"Wu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HEP.0000000000000317","article-title":"P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases","volume":"78","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.tranon.2018.11.012","article-title":"Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6\/STAT3\/PD-L1 pathway in bladder cancer","volume":"12","author":"Zhang","year":"2019","journal-title":"Transl. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.gendis.2019.11.003","article-title":"The hippo tumor suppressor pathway (YAP\/TAZ\/TEAD\/MST\/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis","volume":"8","author":"Zinatizadeh","year":"2019","journal-title":"Genes Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605515\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T07:38:40Z","timestamp":1752133120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605515\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1605515"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1605515","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"1605515"}}